SCHEMBL12190867

SCHEMBL12190867

Cc1cc(F)ccc1NC(=O)c1cncc(-c2ccc(F)cc2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 4/20 0.67
AAK1 Q2M2I8 1/20 0.51
CCNC P24863 1/20 0.51
CDK8 P49336 1/20 0.51
CHRNA7 P36544 1/20 0.50
HDAC1 Q13547 2/20 0.48
KCNH2 Q12809 1/20 0.48
GAA P10253 2/20 0.47
MCHR1 Q99705 1/20 0.47
LMNA P02545 1/20 0.46
THRB P10828 1/20 0.46
ABCB1 P08183 1/20 0.45
XDH P47989 2/20 0.45
ABL1 P00519 1/20 0.45
CYP2C19 P33261 1/20 0.45
GFER P55789 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
CTSA P10619 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12191138 0.93 SCN10A (0.58) SCN10AAAK1CCNCCDK8CHRNA7
SCHEMBL12190921 0.89 SCN10A (0.54) SCN10AAAK1CCNCCDK8CHRNA7
SCHEMBL12191085 0.89 SCN10A (0.66) SCN10AAAK1CCNCCDK8CHRNA7
SCHEMBL12191133 0.88 ABCB1 (0.59) SCN10AAAK1HDAC1KCNH2GAA
SCHEMBL12191075 0.85 SCN10A (0.68) SCN10AAAK1CCNCCDK8CHRNA7
SCHEMBL12191124 0.85 AAK1 (0.50) SCN10AAAK1LMNAABCB1XDH
SCHEMBL12190980 0.85 HPGD (0.57) SCN10ACCNCCDK8ABCB1CTSA
SCHEMBL12190902 0.84 SCN10A (0.60) SCN10AAAK1CCNCCDK8CHRNA7
SCHEMBL12191123 0.83 SMN1; SMN2 (0.55) SCN10ACCNCCDK8GAALMNA
SCHEMBL23181136 0.83 SCN10A (0.62) SCN10AAAK1CCNCCDK8CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030336-B2 Nicotinamide-based kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2011-10-04 US disclosed
US-8030336-B2 Nicotinamide-based kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2011-10-04 US disclosed
US-20070060619-A1 Nicotinamide-based kinase inhibitors CYTOPIA PTY LTD (AU) 2007-03-15 US disclosed
US-20070060619-A1 Nicotinamide-based kinase inhibitors CYTOPIA PTY LTD (AU) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060619-A1 Nicotinamide-based kinase inhibitors NADK, NAMPT, PDXK SCN10A 1066/4885AAK1 169/4885CCNC 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.